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Positive airway pressure and electrical stimulation methods for obstructive sleep apnea 
treatment: a patent review (2005-2014) 
 
Abstract 
Introduction. Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a major health problem 
with significant negative effects on the health and quality of life. Continuous positive airway 
pressure (CPAP) is currently the primary treatment option and it is considered the most effective 
therapy for OSAHS. Nevertheless, comfort issues due to improper fit to patient’s changing 
needs and breathing gas leakage limit the patient’s adherence to treatment. 
Areas covered. The present patent review describes recent innovations in the treatment of 
OSAHS related to optimization of the positive pressure delivered to the patient, methods and 
systems for continuous self-adjusting pressure during inspiration and expiration phases, and 
techniques for electrical stimulation of nerves and muscles responsible for the airway patency. 
Expert opinion. In the last years, CPAP-related inventions have mainly focused on obtaining 
an optimal self-adjusting pressure according to patient’s needs. Despite intensive research 
carried out, treatment compliance is still a major issue. Hypoglossal electrical nerve stimulation 
could be an effective secondary treatment option when CPAP primary therapy fails. Several 
patents have been granted focused on selective stimulation techniques and parameter 
optimization of the stimulating pulse waveform. Nevertheless, there remain important issues to 
address, like effectiveness and adverse events due to improper stimulation. 
 
Article highlights 
i) Limitations of current therapies support the need for novel alternatives in the context of 
obstructive sleep apnea-hypopnea syndrome treatment. 
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ii) A great amount of patents focus on automated adjustment of the delivered breathing gas 
pressure in continuous positive airway pressure devices, which are the primary treatment 
option. 
iii) A novel approach based on electrical stimulation of the hypoglossal nerve currently focuses 
the attention of the medical and scientific communities, as shown by the number of patents 
granted on recent years. 
iv) Implanted neurostimulators avoid common limitations of positive pressure-based devices 
(uncomfortable masks, gas leakage) and surgical procedures (highly invasive, non-reversible) 
becoming a promising treatment option for obstructive sleep apnea-hypopnea syndrome 
patients who refuse positive airway pressure-based therapies. 
 
Keywords: airflow limitation, continuous positive airway pressure, electrical nerve 
stimulation, hypoglossal nerve, obstructive respiratory event, obstructive sleep apnea-
hypopnea syndrome 
 
1. Introduction 
The obstructive sleep apnea-hypopnea syndrome (OSAHS) is a breathing disorder 
characterized by temporary but recurrent complete occlusions (apneas) or partial collapses 
(hypopneas) of the upper airway during sleep. These respiratory events lead to deep oxygen 
desaturations, blood pressure and heart rate acute changes, increased sympathetic activity and 
cortical arousals, which prevent patients from resting while sleeping [1, 2]. The prevalence of 
OSAHS is notably higher in men than in women (2-4:1 ratio in community based studies) and 
it increases with age, body mass index, neck circumference, and waist-to-hip ratio [1-3]. 
Skeletal and/or soft tissues abnormalities in craniofacial and upper airway structure play an 
important role in the occurrence of the disease. In addition, some studies support a genetic 
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predisposition to OSAHS [4, 5]. Regarding related comorbidities, high-risk patients include 
those with congestive heart failure, atrial fibrillation, treatment refractory hypertension, type 2 
diabetes, stroke, nocturnal dysrhythmias, and pulmonary hypertension [6].  
OSAHS has become a major health problem due to its high prevalence and severe negative 
effects on health and quality of life [1, 2, 7]. Both adults and children can suffer from OSAHS. 
Nevertheless, the conditions leading to airway obstruction, its consequences, and the treatment 
are completely different. OSAHS is linked with the most important causes of death in adults 
from industrialized countries. Metabolic deregulation and cardiovascular and cerebrovascular 
diseases, such as atrial fibrillation, stroke, myocardial infarction and sudden cardiac death, 
could affect people having untreated OSAHS [1, 2, 8]. Furthermore, people’s daytime 
performance is severely affected and hypersomnolence due to OSAHS has been linked with a 
higher probability for motor-vehicle collisions and occupational accidents [9, 10]. Regarding 
children, untreated OSAHS leads to several negative consequences in the health and 
development of infants, such as growth impairment, neuropsychological and cognitive deficits, 
and/or even cardiovascular dysfunction [11]. 
Common epidemiological data reflects a high OSAHS prevalence in adults from western 
countries: 1 to 5% of adult men and 2% of women. However, recent studies suggest that 20% 
of adults could have at least mild OSAHS and 7% of adults moderate-to-severe OSAHS [2]. 
Similarly, the American Academy o Pediatrics recently reported that the prevalence of OSAHS 
in children is in the range of 1% to 5% [11]. Life-threatening consequences have augmented 
the interest of the general population on OSAHS, exponentially increasing the number of 
patients for evaluation [12]. Nevertheless, OSAHS is still considered a highly underdiagnosed 
and undertreated disease. Unlike its high prevalence and negative influence in the quality of 
life, it is estimated that 90% of cases in men and 98% of cases in women may be undiagnosed 
for many years [8]. Critical points in the management of OSAHS are both diagnostic 
4 
 
methodology and treatment compliance. Diagnosis starts with an initial subjective evaluation 
of the sleep history, which highly depends on the symptoms reported by the patient. Next, 
according to the risk for OSAHS determined by the physician, overnight attended in-laboratory 
polysomnography (PSG) or portable monitoring (PM) at home is prescribed [6, 13]. In-lab PSG 
has been the standard method for OSASH diagnosis. During PSG, the patient’s sleep is 
monitored by means of several sensors during at least one whole night in hospital facilities. The 
analysis and subsequent interpretation of the results is complex and time consuming, leading to 
large waiting list [3, 14, 15]. Currently, portable home sleep monitoring has emerged as an 
alternative for OSAHS diagnosis [3]. According to the AASM rules, PM may be used in 
patients with a high pre-test probability of moderate-to-severe OSAHS and with no other major 
comorbid condition or sleep disorder [6, 13, 15]. On the other hand, regarding OSAHS 
treatment, there are different approaches, including non-invasive therapies such us positive 
airway pressure (PAP) devices aimed at maintaining the patency of the upper airway, or 
invasive and irreversible surgical operations that alter the patient’s anatomy, such as 
maxillomandibular advancement, hyoid suspension or uvulopalatopharyngoplasty [3, 6].  
Continuous positive airway pressure (CPAP) is the gold standard treatment for OSAHS [16]. 
According to the recommendations of the AASM, CPAP is indicated for the treatment of 
moderate-to-severe patients [6]. Individual titration of the pressure level for each patient is 
needed. The standard procedure is based on the determination of the continuous pressure that 
normalizes the patient’s sleep and breathing during in-lab PSG [17]. However, CPAP titration 
at patient’s home is a widespread alternative procedure due to large waiting lists in many sleep 
labs [18]. OSAHS is a chronic disease hence long-term treatment is needed. Existing therapies, 
however, are not consistently effective for all patients and user’s acceptance and therapy 
compliance is below desired levels [6, 19, 20]. 
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The present review focuses on recent patents related to OSAHS treatment granted in the last 
ten years (from 2005 to 2014). Firstly, inventions aimed at minimizing limitations of continuous 
positive airway pressure (CPAP), which is currently the primary treatment option for OSAHS, 
are analyzed. Finally, patents linked with electrical nerve stimulation of the hypoglossal nerve, 
which have shown an increasing interest as a reliable alternative to CPAP, are also discussed. 
 
2. Obstructive sleep apnea-hypopnea syndrome (OSAHS) 
2.1. OSAS diagnosis 
Diagnostic criteria for OSAHS are based on clinical signs and symptoms determined during (i) 
an initial sleep evaluation including sleep oriented history and physical examination and (ii) 
further comprehensive objective testing by means of in-laboratory full-night PSG [6]. Common 
topics in the patient’s sleep history should include evaluation of snoring, witnessed apneas, 
choking episodes, excessive daytime sleepiness, total sleep amount, nocturia, morning 
headaches, sleep fragmentation, and decreased concentration and memory. High-risk patients 
with nocturnal symptoms should undergo overnight PSG. For the remaining patients, the timing 
of further sleep testing is determined by the presence of daytime symptoms or comorbidities 
[6].  
During standard PSG, neurophysiological and cardiorespiratory signals are recorded to 
subsequently analyze sleep and breathing. Thus, electroencephalogram (EEG), 
electrooculogram (EOG), chin and leg electromyogram (EMG), electrocardiogram (ECG), 
airflow (AF) by means of thermistor and nasal prong pressure transducer, oximetry, body 
position, snoring sounds, and video are commonly recorded during the whole night. Every sleep 
study should be analyzed and interpreted by a qualified physician. The American Academy of 
Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events define 
practice parameters, technical specifications, and event scoring rules aimed at minimizing inter-
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scorer variability and improving the quality of the diagnosis [6]. Apnea is defined as a 
significant reduction (> 90%) of airflow for more than 10 s, whereas hypopnea is defined as a 
decrease in respiratory flow of at least 50% (or alternatively 30%), accompanied by a 
desaturation greater than or equal to 3% (alternatively 4%) and/or an EEG arousal. The apnea-
hypopnea index (AHI), which is the average number of apnea and hypopnea events per hour of 
sleep, is the standard index used to diagnose OSAHS and establish its severity [21]. A positive 
diagnosis is confirmed if AHI  15 or if AHI  5 e/h in a patient reporting any of the following 
symptoms: daytime sleepiness, un-refreshing sleep, fatigue, insomnia, waking up breath 
holding, gasping, or choking, or the bed partner describing loud snoring breathing interruptions 
or both during the patient’s sleep [22]. Usually, OSAHS severity is defined as mild 
(5AHI15), moderate (15AHI30), and severe (AHI>30) [6]. A split-night study, which 
consists on an initial standard PSG followed by CPAP titration on the same night if an AHI  
40 e/h is scored during 2 hours, is an alternative [23].  
On the other hand, complete PSG is considered labor-intensive, expensive and time-consuming 
[24], leading to increased waiting lists and delayed access to diagnosis and treatment [14]. Thus, 
there is a great demand on new techniques aimed at simplifying the standard procedure and/or 
reducing the number of PSGs needed (screening tests) [25]. The main alternatives to PSG focus 
on portable monitoring [24, 26]. Portable monitors are usually classified as type 1 or standard 
PSG; type 2, which include sleep staging and respiratory measures; type 3, which use at least 
three respiratory channels; and type 4, which use at least one respiratory channel, usually 
oxygen saturation or airflow [24]. In addition, automated signal processing techniques have 
been widely applied during the last years to improve the diagnostic ability of single-channel 
cardiorespiratory recordings. In this regard, single-lead ECG [27, 28], single-channel AF [29, 
30, 31] and blood oxygen saturation (SpO2) from nocturnal pulse oximetry [25, 32, 33] have 
been predominantly studied. In order to standardize portable monitoring assessment and help 
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physicians to uniformly classify and properly evaluate sleep testing devices, different studies 
have been carried out during the last years [24, 26, 34]. 
2.2. OSAHS treatment 
Surgical (nasal, oropharyngeal and hypopharyngeal procedures, maxillomandibular 
advancement, and hyoid suspension), medical (CPAP, custom-made oral appliances), 
behavioral (weight loss, positional therapy), and pharmacological (supplemental oxygen, 
modafinil) approaches are currently the main alternatives for OSAHS treatment [3, 6, 20, 35, 
36]. Table 1 summarizes the main alternatives currently available for OSAHS treatment, their 
advantages and limitations. 
CPAP, which was first described by Sullivan in 1981 [37], is considered the standard of care 
for OSAHS [6, 38]. Currently, CPAP is the primary preferred treatment of mild, moderate and 
severe OSAHS. It should be offered as an option to all severe patients or mild to moderate 
patients showing daytime and/or nocturnal symptoms [6]. There are strong evidences on the 
effectiveness of CPAP in decreasing symptoms of sleepiness, reducing cardiovascular risk, and 
improving quality of life in patients suffering from moderate and severe OSAHS [20, 38, 39]. 
In addition, it has been shown that treatment with CPAP significantly reduces the mortality 
associated to the disease [40]. On the other hand, although several studies report significant 
benefits of CPAP treatment for mild patients, several uncertainties still remains [20, 38]. During 
CPAP treatment, the patient sleeps wearing a mask connected to a gas flow generator via a 
tubing system aimed at delivering a continuous positive pressure of air to keep the airway open 
[3]. The therapy pressure is constant during the whole night and must be determined during a 
sleep study (titration) to obtain the optimum value to maintain the airway patency. Though non-
invasive, simple and highly effective, CPAP treatment delivers the same constant high pressure 
both during inspiration and expiration phases, which is unnecessary. Modification of expiratory 
pressure contour is a technical advance aimed at improving patient’s comfort by reducing 
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pressure at the beginning of the exhalation. C-Flex (Philips Respironics, Murrysville, PA, USA) 
and EPR (ResMed, San Diego, CA, USA) are commercial solutions. Nevertheless, there is not 
scientific evidence that this technical advancement leads to an improvement in adherence or 
comfort. Side effects of CPAP are air leakage, skin irritation, mouth dryness, nasal discharge 
and even claustrophobia and panic attacks [3, 19]. In fact, poor compliance (CPAP usage less 
than 4 hours per night) ranges from 30% to 80% [41] and refusal of treatment is estimated in 
up to 40-50% of patients [42].  
Bi-level positive airway pressure (BPAP) is an improvement over conventional CPAP therapy. 
BPAP devices deliver two different pressures: a pressure during patient’s inspiration 
(inspiratory pressure, IPAP) and a lower pressure during expiration (expiratory pressure, 
EPAP), which fits better with patient’s natural needs. Nevertheless, bi-level devices also 
maintain a constant high pressure during the whole inspiration phase (aimed at overcoming 
airway obstruction) and a different lower but constant pressure during the whole expiration 
phase (aimed at decreasing the pressure against which the patient exhales) [3, 43]. Therefore, 
BPAP therapy suffers from the same limitations than CPAP regarding comfort and treatment 
compliance. Furthermore, fluctuations and asynchrony between pressure changes (from IPAP 
to EPAP and vice versa) and patient’s respiration can increase patient’s discomfort [43]. On the 
other hand, it has been shown that pressure needed to avoid obstructive events varies during the 
treatment period due to changes in weight, medication and habits, and even through each single 
night, depending on sleep stage or body position [43, 44]. Autotitrating or auto-adjusting CPAP 
(auto-PAP) is an alternative aimed at improving adherence to therapy. Auto-PAP devices 
optimize the level of continuous pressure through the night, reducing overall mean pressure and 
minimizing patient’s discomfort due to size effects [19]. It is important to emphasize that BPAP 
and APAP are technical advances with no proven enhancement over conventional CPAP from 
a clinical point of view. Although these technologies have been shown to be safe and effective, 
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no compliance or clinical benefits have been demonstrated [16]. Furthermore, there are several 
studies reporting there is not significant improvement in comfort, patient’s quality of life, 
treatment adherence and/or a decrease in symptoms when APAP devices are used instead of 
conventional CPAP [19, 43, 45-50]. 
Common alternatives to CPAP treatment include oral appliances and surgical procedures, both 
aimed at correcting anatomic abnormalities which lead to narrowing and obstruction of the 
upper airway during sleep [51]. Regarding oral appliances, there exist two main approaches [6, 
35]: (i) tongue retaining devices, which hold the tongue in a forward position with respect to 
the resting position, and (ii) mandibular repositioning appliances, which cover the upper and 
lower teeth and hold the mandible in an advanced position with respect to the resting position. 
The later is currently the most widely used oral appliance [35]. Although CPAP is the most 
reliable therapy and should be offered to all patients, oral appliances can be an effective 
alternative treatment in patients with mild to moderate OSAHS who do not respond to positive 
pressure delivery and/or life style modification strategies [6]. Oral appliances are the only non-
invasive alternative to CPAP that can reach favorable results within a short time. However, this 
treatment modality is considered still underutilized [35]. Regarding surgical therapy, there are 
different upper airway reconstructive procedures [6]. In this way, maxillomandibular 
advancement osteotomy leads to a permanent increase in volume and reduction in length of the 
upper airway that is correlated with improvement in AHI [52]. Therefore, it could be an 
effective therapeutic option for severe OSAHS patients who do not respond to primary CPAP 
or oral appliances [53]. Similarly, surgery can be also considered in mild OSAHS patients who 
have severe but surgically-correctable obstructing anatomy [6]. However, surgical techniques 
are highly invasive and irreversible hence there is still a great demand for novel feasible 
therapies. 
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Although oral appliances and surgical procedures are common alternatives in patients who are 
intolerant to CPAP, they also have important limitations. To overcome these drawbacks, novel 
non-CPAP therapies have emerged [52, 54]. The nasal expiratory positive airway pressure 
(EPAP) (Provent sleep therapy, Ventus Medical Inc., USA) is a unidirectional flow-resistant 
device aimed at regulating airflow through the nostrils (expiratory flow resistance without any 
inspiratory resistance). Different studies have been conducted to assess its effectiveness [55, 
56]. Significantly (p<0.001) reduction in AHI compared with initial PSG were reported in mild, 
moderate and severe OSAHS patients. However, AHI reduction was less than 50% and severe 
nocturnal desaturations and persistent nasal blockage were reported, which limit adherence to 
treatment [54]. A novel oral pressure therapy (OPT) has been also proposed. Winx (Apnicure 
Inc., USA) is a commercial OPT-based device that applies a vacuum to the oropharynx to pull 
the soft palate forward and stabilize the tongue in order to maintain airway patency [54]. Colrain 
et al. assessed the safety and effectiveness of the Winx device in a population composed of 
mild-to-severe OSAHS patients. Clinically significant improvement in AHI, sleep quality and 
continuity, and daytime sleepiness were reported [57]. Nevertheless, further work is needed to 
confirm the effectiveness of such devices as reliable alternative to conventional CPAP therapy. 
In contrast to the use of physical/technical devices, drug-based treatments have been also 
proposed for OSAHS. Oral drugs approaches focuses on 5 strategies: increasing ventilatory 
drive, increasing upper airway tone, decreasing REM sleep, increasing arousal threshold, and 
increasing the cross-sectional area (or reducing the surface tension) of the upper airway through 
topical therapy [52]. Although some drug-based therapies may be helpful, additional work is 
still needed to demonstrate their long-term tolerability and efficacy [52]. 
Nerve stimulation to control the position of the tongue is a promising alternative. Upper airway 
dilator muscles play an important role in maintaining upper airway patency during sleep [42]. 
Different studies suggest that electrical stimulation of the hypoglossal nerve and genioglossus 
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muscles using implanted electrodes could lead to significant reductions in upper airway 
resistance [42]. Moreover, selective stimulation of both the lateral XII nerve branches and the 
medial nerve branch seems to increase maximum rate of airflow and mechanical stability [42, 
58, 59]. Recent studies assessing efficacy of current commercial devices for electrical 
neurostimulation report significant improvement in AHI and quality of life measures [60-62]. 
However, PSGs at 6 and 12-month follow up yielded an average decrease in AHI ranging from 
53% to 68%, with a final average AHI varying from 9.0 (4.2 to 22.5 interquartile range) to 19.5 
 16.7 (mean  standard deviation, SD), suggesting unequal efficacy, especially in obese 
patients (BMI  35 kg/m2). On the other hand, limitations of this approach are coarse (non-
selective) stimulation of nerves and muscles, fatigue associated to inappropriate stimulation 
frequency and duration, induced arousals linked with inaccurate stimulation amplitude, 
inaccurate detection of obstructive events, and asynchronous detection and stimulation modules 
[42, 63]. Electrical stimulation of the whole nerve results in combined contractions of both 
intrinsic and extrinsic muscles, and both retrusor and protrusor muscles, leading to undesirable 
sensory stimulation and lateral deviation and retrusion of the tongue [63]. Another common 
issue linked with artificial electrical stimulation of muscles is fatigue due to the stimulating 
electrode is essentially in a fixed position and the same population of fibers is continuously 
activated [63]. Although these technical issues have been solved in current available devices, 
important limitations still remain, such as surgery related complications (transient tongue 
paralysis), device malfunctions (transient asynchronous stimulation/interruption and electrode 
breakage) and/or tongue abrasion [54, 60, 61]. 
In the following sections, recent granted patents (granted from 2005 to 2014) linked with 
improvements of the standard therapy for OSAHS (CPAP) and the novel electrical nerve 
stimulation are described. Table 2 summarizes reviewed patents. Firstly, inventions related to 
PAP therapy are analyzed. Patents are presented according to the approach or kind of device 
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proposed by the inventors: auto-adjusting PAPs, bi-level PAPs, and novel devices. Secondly, 
patents linked with electrical nerve stimulation are analyzed. Inventions are grouped by type of 
stimulation: continuous vs. event triggered. Finally, a methodology for assessing electrical 
nerve stimulation-based therapy success before surgery is analyzed. 
 
3. Positive airway pressure devices 
Determining the minimum pressure that fits the patient’s needs has been a major goal of 
research regarding CPAP treatment. It has been shown that this minimal pressure varies along 
time according to different variables: sleep stage, body position, weight, medication, and/or 
patient’s habits [43, 44]. In this regard, Rapoport et al. have been granted a set of patents in 
Australia [64], Europe [65, 66], Canada [67], and USA aimed at automatically detecting airflow 
limitation and computing the optimal pressure for the user [68-72]. In [70], airflow limitation 
is detected by computing four shape-based parameters derived from the present and the 
preceding breaths: sinusoidal index, flatness index, respiratory effort index and relative flow 
magnitude index. All these shape-derived parameters are combined (e.g. by logistic regression) 
to obtain a single measure showing the probability that the current breath has a shape 
characteristic of flow limitation. Finally, prior probability measures from preceding breaths 
modify the weight of the current flow limitation index. The proposed self-adjusting system can 
be used either with a positive pressure device or just for determining the frequency and severity 
of flow limitations. Similarly, a system aimed at detecting airflow limitations is described in 
[71]. The main novelty of this invention is the application of a pre-trained artificial neural 
network to classify individual patient’s breaths into the following classes: flow limitation is (i) 
present, (ii) probably present, (iii) not probably present, and (iv) not present. Flow and/or 
pressure signals including a plurality of patient’s breaths are segmented and parameterized to 
feed the neural network. In [72], a system, method and apparatus for OSAHS treatment are 
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described, aimed at minimizing the airflow pressure while still avoiding flow limitation. The 
proposed system increases or decreases the airflow pressure in response to inspiratory airflow 
changes, such as significant deviation from a sinusoid, flattering or the presence of plateaus. 
According to the inventors, a time weighted majority function is applied to the flow limitation 
parameter values for a certain number of previous breaths and an automated decision tree is 
used to decide whether to change the positive controlled pressure taking into account flow 
limitation indexes of the current and the preceding breaths and previous decisions of the system. 
Eklund et al. [73] have been granted a patent for the detection and treatment of disordered 
breathing during sleep based on artificial neural networks. The invention automatically adjusts 
the delivered pressure based on the presence of respiratory events. According to the inventors, 
the flow or pressure signal in the CPAP circuit is continuously monitored using a constant 
sampling frequency. This signal is periodically parameterized by computing respiration-related 
variables (cepstrum coefficients and the energy trend parameter), which are fed to the artificial 
neural network (Kohonen’s self-organizing maps) in order to recognize patterns characteristic 
of airflow limitation. Sleep disordered breathing is determined if the number of outputs of the 
network during a selected interval exceeds a preselected threshold value. Accordingly, the 
amount of breathing gas provided to the patient is increased until a normal breathing pattern is 
re-established. 
Similarly, Waxman et al. have been recently granted a patent for the detection and prediction 
of physiological events in people suffering from sleep disordered breathing [74]. The proposed 
system pre-processes (segmenting, transforming and encoding stages) physiological input data 
and feeds a neural network to predict sleep-related breathing events within the next 60 s in order 
to control airway pressure levels generated by PAP devices. In preferred embodiment, the 
Authors propose to use the Wavelet transform in the pre-processing stage and the Large 
Memory Storage and Retrieval (LAMSTAR) neural network in the pattern recognition stage. 
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Similarly, in [75], the Authors describe a learning control system based on one or a plurality of 
artificial neural networks aimed at controlling the breathing support for increasing effectiveness 
of PAP-based therapies. 
The use of signal processing techniques is a common feature of this group of patents. They 
apply different pattern recognition methodologies (logistic regression, neural networks and 
decision trees) to detect respiratory events and regulate the pressure level while allowing 
estimating the AHI during the treatment. This technology has been incorporated by different 
CPAP manufactures, such as Philips Respironics, ResMed, Fisher & Paykel or Breas, enabling 
clinician follow-up and CPAP effectiveness assessment. However, further studies are needed 
to evaluate whether this information can improve CPAP adherence. 
Detecting when the patient is asleep or awake is a novel promising approach for increasing 
patient’s comfort [76, 77]. In this regard, Rapoport et al. have been granted a patent for 
adjusting the positive airway pressure supplied to a patient [78]. The patient’s breathing patterns 
are analyzed by a signal processing algorithm in order to detect the following patient’s states: 
(i) regular breathing, (ii) sleep disordered breathing, (iii) REM sleep, and (iv) troubled 
wakefulness. The signal processing system monitors airflow and pressure signals from 
conventional flow sensors coupled to the PAP device. If pure mouth breathing, erratic large 
breaths with varying inspiratory times, or irregularity of intervals within breaths (but not cyclic 
apneas) are detected, then the system determines whether the patient is awake and anxious or 
distressed (troubled wakefulness). Then, the pressure applied by the PAP device can be 
lowered, which should improve the user’s comfort until the patient falls asleep. Resumption of 
regularity or detection of cyclical and regular respiratory events characterizes breathing patterns 
when a patient is asleep. In [79], the invention by Rapoport et al. describes a therapeutic 
pressure mode when the system determines that the patient is asleep while a sub-therapeutic 
pressure mode is applied when the system determines that the user is awake. Similarly, in the 
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invention described by Nightingale et al. [80], the proposed system provides a sub-therapeutic 
pressure level at the beginning of the treatment session or when wakefulness is detected while 
operating in a therapeutic delivery mode when the patient is asleep. The system determines if 
the patient falls asleep by comparing the elapsed time since the last conscious user interaction 
with the system (e.g. activating a button from the user’s interface) or since the device was turned 
on with a threshold. This value may be fixed (averaged user sleep patterns), settable (by the 
user or the physician) or adaptive (dependant on current and/or past breathing patterns). In both 
patent applications [79, 80] the Authors suggest to use the methodology proposed in [78] to 
decide whether the patient is awake or asleep. Leading CPAP manufactures, such as ResMed 
and Fisher & Paykel incorporate this technology into their commercial devices. Although some 
studies have assessed the effectiveness of these techniques for sleep onset and awakening 
detection [76, 77], further investigation is needed to evaluate their actual long-term influence 
on patient’s comfort and CPAP compliance. 
A proportional PAP (PPAP) device has been granted in Australia [81], Canada [82], Europe 
[83, 84] and the USA [85-87]. The main characteristic of the proposed invention is that the 
breathing gas is delivered to the patient at a minimally sufficient pressure during at least a 
portion of the breathing cycle to prevent airway collapse. Two operating parameters allow for 
controlling the delivered pressure: (i) a first gain or inspiration gain, which modifies (multiplies) 
the current estimated flow rate in order to compute the pressure during inspiration, and (ii) a 
second gain or expiration gain, which is used during exhalation to reduce the delivered pressure 
based on the current estimated flow rate. Patent [87] is a continuation of previous patent 
documents. In this invention, it is described a method and an apparatus for determining whether 
the patient is experiencing obstructive or central apneas based on the output of a sensor. A 
comparison between a short-term average of peak inspiratory flow rate or tidal volume (e.g. a 
3 breath average) and a long-term average (e.g. greater than 20 breaths) is computed. Once an 
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apnea is detected, the system automatically increases the inspiration gain, waits approximately 
1 second, and then decreases the pressure back to the original value. If a significant change in 
the airflow is detected, then the system concludes that the airway is open (central apnea), 
whereas if there is no significant change, the system concludes that the airway is closed 
(obstructive apnea). 
W.D. Childers & R.O. Childers [88, 89] have been granted a pair of patents linked with the 
automated setting at-home of a PAP device in order to manage/adapt to patient-to-patient 
variations and/or changes in particular patient’s conditions. The proposed method and apparatus 
includes 2 different operating modes: standard and custom. The custom operating profile is 
characterized by customized parameters based on a prescription according to the patient’s 
therapeutic needs, including increased maximum therapeutic pressure, initial pressure and 
duration prior to an obstructive event and incident pressure and duration during an obstructive 
event. In addition, operating parameters can be optimized for long term therapy or for transient 
conditions (e.g. temporary nasal congestion). The inventors suggest the use of a backlit LCD 
or OLED touch screen as user interface and an USB or wireless RFID link to communicate with 
the system controller. The main novelty of this invention is the description of the user interface 
for automated setting of the device at-home according to the changing patient’s therapeutic 
needs. As previously stated, at-home diagnosis and treatment is the focus of physicians and 
manufactures due to the chronic and variable nature of OSAHS. Therefore, novel devices may 
incorporate this technology to allow user interactions that could increase patient’s comfort and 
treatment compliance. 
Recently, J. Sun [90, 91] has been granted a patent for providing bi-level positive pressure to a 
patient. Sun proposes a novel technique to avoid the delay between the detection of inspiration 
and expiration stages in the respiratory cycle and the adjustment of the required pressure (IPAP 
or EPAP). De-synchronization could lead bi-level therapies to fail if the computed pressure at 
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the end of the last expiration is lower that the optimal pressure needed to avoid the airway 
collapse in the present inspiration. An expiratory unloading factor is computed based on the 
correlation between the inspiratory (expiratory) pressure and the inspiratory (expiratory) motor 
load generating the flow of air. Two sensors (an airflow pressure sensor and a load sensor) are 
used to generate the pressure signal and the load signal. The expiratory unloading factor 
indicates the difference in the motor load required to generate the inspiratory and expiratory 
pressures at the patient interface. 
M. D. Hallet [92] describes a method for providing bi-level automatic respiratory support for 
treatment of sleep disordered breathing. This invention is aimed at automatically detecting the 
user’s need to initiate lung empting (expiration) in order to provide a lower pressure. In 
addition, the system is also designed to minimize patient’s effort during inspiration to achieve 
airway stability. Delivered pressure is governed by respiratory-related parameters, such as rate, 
tidal volume, average minute ventilation, presence of residual inspiratory effort, and based on 
average quiet, stable breathing levels over the past 2 to 10 minutes (moving average minute 
monitoring). Upper and lower delivered pressures are adjusted if airway instability or 
inspiratory flow resistance (flow limitation) are detected. 
Although non-fixed pressure devices are becoming more commonly prescribed in some 
countries [93], regarding the reviewed patent documents, there have been no major changes in 
BPAP and APAP devices for OSAHS during the last decade. Comfort and effectiveness have 
improved because PAP-based devices are smaller, integrate humidification, and airway 
pressure is delivered in novel ways. Technological advances such as the use of multiple sensors, 
signal processing algorithms and control modules have enabled fine control of the pressure 
level delivered to the patient. Nevertheless, the operating principle, i.e. deliver a positive 
pressure to maintain airway patency, is not different than in those manufactured in the last 10-
20 years. 
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A complete enclosure was developed by D. Grady [94] for the treatment of OSAHS, which 
consists in a base connected to a bed, a canopy connected to the base and a sealing member that 
connects the canopy to the base, so that both elements form a substantially airtight enclosure 
around at least a portion of the bed. A conventional CPAP can be connected to generate 
continuous positive airway pressure within the whole enclosure. The main feature of this 
invention is that continuous positive pressure is delivered to the patient without the need for a 
fitted mask, which avoids common compliance issues of conventional treatment. Additional 
benefits described in the invention are control of humidity and temperature within the 
pressurized enclosure and attenuation of sound and light in order to facilitate sleep. On the other 
hand, the proposed invention is far away from the current trend of leading manufactures, which 
focus on developing smaller and portable devices. 
P.J. McAuliffe and D.L. Bullock [95-100] have been granted a set of patents for controlling the 
pressure and/or flow rate of breathable gases by means of a flow diverter valve during non-
invasive positive pressure ventilation therapy. The aim of this invention is to reduce noise and 
to improve the blower motor response time in order to prevent patient discomfort. To achieve 
this goal, the inventors describe (i) a flow diverter valve with reduced noise, flow fluctuations 
and increased response speed, and (ii) a valve assembly with a flow diverter rotatable vane that 
does not choke a blower regardless of the vane position. The position of the rotatable vane 
changes according to patient’s needs dividing the airflow between an exhaust and an outlet port. 
The aerodynamic characteristics of the vane (and thus the flow characteristics and the response 
time) depend on specific parameters, such as the radii of curvature, the distance between centers 
of the radii of curvature and the leading vane corners, the position of the rotator vane within the 
device, and the width and length of the flow paths. 
Previous reviewed patents focused on different methodologies for controlling the airflow 
pressure level delivered to the patient during expiration and inspiration. However, an important 
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issue concerning the comfort and successfulness of the treatment is linked with the mask, which 
is in direct contact with the patient. Mask technology focused the attention of manufactures 
during the last years. In fact, performance of existing respiratory masks is noticeably higher 
than preceding ones and may be responsible for the improvement in therapy compliance and 
user’s comfort over the past decade. The most important limitation of these masks is the 
leakage, i.e. undesirable escape of the gas under pressure. This problem is two-fold: in one 
hand, leakage negatively impacts the treatment efficiency and, on the other hand, it causes 
important discomfort for the patient. The invention by Luca et al. [101] describes an improved 
membrane cushion able to provide efficient mask tightness whatever the patient’s 
physiognomy. Fitness to different patient’s faces is achieved by using cushion membranes of 
different thicknesses in different regions of the mask (upper nasal bridge, cheek regions on both 
sides of the nose and lower chin region under the mouth). Efficient gas tightness and increasing 
comfort for the patient depends on specific parameters specified by inventors, such as 
thicknesses of internal and external membranes of the cushion in the different regions and a 
variable number of cuts in the central portion of the cushion. Similarly, Lithgow et al. [102] 
have been granted a patent for controlling the distribution of contact force of a respiratory mask 
around the patient’s face. In this invention, uncomfortable high pressure along sensitive regions 
of the patient’s face, e.g. nasal bridge and lip region, is reduced to increase user’s comfort while 
maintaining the cushion seal. This is accomplished by varying the size, shape, geometry and 
materials of different external and internal structures of the cushion (membranes, rims, gusset 
areas and outer/inner edges). In [103], Barnett et al. describe a nasal mask with a flexible sealing 
element including a structural reinforcement area of increased thickness around the perimeter 
of the cushion. A saddle shaped contoured area is included on each side of the sealing member, 
each one having upper and lower protrusions for providing supporting contact with the face. In 
addition, the distal portion of the cushion includes an in-turned lip that is turned toward the 
20 
 
nose receiving cavity. The degree of roll of the lip controls the contact area of the mask-patient 
interface and it can be increased or decreased depending on the desired seal and patient’s 
comfort. 
 
4. Electrical nerve stimulation 
Recurrent airflow cessations characteristic of OSAHS have been linked with a decline in the 
upper airway neuromuscular activity during sleep [104]. This knowledge has supported the 
development of several patents related to electrical nerve stimulation of the hypoglossal nerve 
as a novel treatment for OSAHS. In this regard, Lima & Craig [105, 106] have been granted 
two patents for treating OSAHS based on a RFID-enabled microelectronic neurostimulator 
system. A transponder located in the implant (a passive RFID transponder or an active 
transponder) allows for the communication with the external subsystem. The inventors suggest 
that this external subsystem may be shaped for placement around a patient’s ear or with a patch 
placed in the skin. Electrical nerve stimulation depends on patient-specific nerve physiology 
and parameters that can be set in a controller (frequency, amplitude of the signal, number of 
electrodes involved in the stimulation, among others). One of the main characteristics of this 
invention is selective stimulation of both hypoglossus and styloglossus, which results in an 
increased maximum rate of airflow and mechanical stability of the upper airway. This is done 
by using a matrix arrangement of electrodes that provides multiple nerve stimulating points: 
different nerve fascicles can be accessed enabling selective stimulation of a particular area of 
the nerve. The patent describes different stimulation modes: continuous, i.e. constant 
stimulation to maintain tongue muscle tone typically during sleep hours, and upon 
preprogrammed conditions, i.e. under patient-specific intervals, both during sleep hours and 
while the patient is awake. 
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Recent patents by Meadows et al. granted in Australia [107] and USA [63, 108] described a 
novel methodology for the selective electrical stimulation of the motor efferents of the 
hypoglossal nerve. To achieve this goal, a programmable electrode is used. It is composed of a 
plurality of contacts for the selective activation of targeted nerve fibers (motor neuron 
subgroups) within a nerve bundle and, consequently, their associated motor groups (innervated 
muscles). According to the inventors, the stimulation is controlled by different parameters, such 
as stimulation onset, amplitude (gradual ramping from threshold to target amplitude), frequency 
and duration. In addition, inventors describe a system to minimize fatigue based on the 
modulation of the amplitude of the stimulating signal, so that stimulation is applied for a certain 
amount of time and then stopped to let the muscles rest (stimulation duty cycle). Electrical 
stimulation is applied to different fiber groups using different contacts placed in the fixed 
stimulating electrode, so that none of the groups is activated long enough to cause significant 
fatigue. In addition, the frequency of the stimulation is reduced because higher activation 
frequency leads to higher fatigue. The inventors obtain the desired functional stimulation rate 
as the sum of the rates of different fiber groups working together (overlapped activation) but 
activated sequentially (delayed activation). According to the inventors, this activation 
methodology allows for a continuous or near-continuous (open loop) stimulation of the tongue, 
so that there is no need to synchronize activation and breathing or to monitor for apneas using 
additional sensors and signal processing techniques. Therefore, the system complexity 
decreases, as well as the surgical procedure complexity, power consumption, and the whole 
cost. 
A recent group of patents by McCreery [109-111] described an apparatus, a system and a 
method for the treatment of OSAHS based on the electrical stimulation of the hypoglossal 
nerve. The invention comprises a sensor to monitor both the position of the tongue and the force 
exerted against the sensor and a set of electrodes to deliver electrical stimuli to the ventral 
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surface of the tongue. In a normal state, the tongue is extended and contacts the sensor exerting 
a force against it, whereas during apneic events the airway collapses due to the reduction of the 
tone of the muscles of the upper airway accompanied by the prolapsed of the tongue base onto 
the airway. The proposed system detects that the tongue is in a posterior position and delivers 
a train of electrical stimuli to the branches of the motor nerves innervating muscles that protrude 
the tongue to move it to an anterior position in order to avoid obstruction of the airway. The 
proposed sensor comprises an emitter (e.g. LED) and a detector (e.g. phototransistor). The 
position of the tongue is monitored measuring the intensity of pulsed infrared light from the 
emitter that is back-scattered from the tongue to the detector. 
A group of patents by Bolea et al. [112-116] describe a fully or partially implantable 
neurostimulator system of the hypoglossal nerve. Claims in patent documents [112, 113, 115] 
focus on different electrode configurations, whereas claims from patent [116] mainly focus on 
signal processing and triggering techniques. In patent document [114], the inventors include 
additional information about external control devices, physical electrode characteristics and 
accommodation techniques, methods for detecting sensor failure, alternative nerve stimulation 
sites (e.g. cranial root of the accessory nerve or superior laryngeal nerve), additional techniques 
for automated monitoring and processing of respiration in order to trigger stimulation, and new 
characteristics of the stimulating pulse waveform. In a preferred embodiment, electrical 
stimulus is triggered as a function of the respiration, which is monitored by the implanted or 
external respiration sensing leads in a close-loop feedback system. The following signal 
processing stages are specified to obtain a usable trigger signal for stimulation: amplification, 
filtering, artifact removal (cardiac and motion artifacts), detection of fiducial points (inspiration 
and expiration onset derived from the first and second derivative of the respiratory signal), and 
special events detection (obstructive and central apneas, hypopneas, sleep stages). The 
following respiratory derived parameters are used: peak-to-peak (PP) magnitude, coefficient of 
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variation (CV) of the PP magnitude, maximum and minimum PP amplitudes (PPmax and 
PPmin), and PP range. According to the inventors, the stimulus is delivered just from the 
beginning to the end of the inspiration phase of the respiratory cycle in order to minimize nerve 
and muscle fatigue. A self-adjusting predictive trigger algorithm based on the estimation of the 
inspiratory onset from previous respiratory cycles (reference/historical fiducial data) is used, 
which is specific to a person, sensor location, sleep stage, and sleep position, among other 
factors. Alternatively, the electrical neurostimulation system may also operate in an open-loop 
process, where stimulus is derived according to a preprogrammed parameter setting. 
In a patent by Tesfayesus et al. [117], a complementary methodology for assessing the 
likelihood of therapeutic success of electrical stimulation of the hypoglossal nerve for treating 
OSAHS before the surgery is described. According to the inventors, this stage is necessary 
because response to hypoglossal nerve stimulation varies across subjects. To achieve this goal, 
the inventors propose a methodology for observing the patient’s upper airway during a tongue 
protrusion maneuver, which mimics the effect of genioglossus activation by hypoglossal nerve 
stimulation: the larger the airway size increase during the process, the larger subsequent 
therapeutic benefit for the patient. The upper airway is observed by endoscopy while the patient 
is awake and supine. 
The Upper Airway Stimulation (UAS) system by Inspire Medical Systems Inc. (Maple Grove, 
MN, USA) is a fully implanted device for electrical stimulation of the hypoglossal nerve. The 
Inspire II is the second generation of the UAS system and it has been recently approved by the 
Food and Drug Administration (FDA) for commercialization in the context of OSAHS 
treatment. It is important to point out that Inspire Medical Systems is a Medtronic’s spin-off, 
which decided to spin out this technology and its related patents in 2007. In this regard, Inspire 
Medical Systems is currently the owner of a significant patent portfolio related to electrical 
nerve stimulation for treating sleep disordered breathing, which has led to the recent FDA 
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approval. In addition, novel patents regarding the management of the implantable 
neurostimulation system [118], a methodology for suitable patient selection for therapy [119], 
and nerve cuff characteristics [120] have been recently granted. Furthermore, patent 
applications associated with minimally invasive techniques for insertion of sensing and 
stimulation leads [121, 122], suitable electrode positioning [123], and a methodology for 
monitoring the respiratory effort to control the therapy level [124], are currently under review. 
Regarding the granted patents, Christopherson et al. have been recently granted a system for 
automatically initiating and adjusting therapeutic treatment of sleep apnea [118]. The patent 
document focuses on an automatic therapy manager. The invention comprises a sensing module 
aimed at monitoring respiration and body position (activity and posture sensors), an implantable 
pulse generator in communication with the sensing module, and an automatic therapy manager 
for delivering (or stopping) electrical nerve stimulation when sleep disordered breathing (or 
normal sleep) is detected. The therapy manager is aimed at optimizing treatment (i) by 
performing variable sampling of physiologic conditions (higher sampling rate during periods 
of lower patient activity corresponding to higher likelihood of sleep) and (ii) by managing 
transitions between states of operation according to physiological-based criteria (a severity 
score based on quantity, duration and intensity of airway obstruction is computed and electrical 
stimulation is delivered/stopped accordingly). On the other hand, this kind of therapy is more 
expensive than the standard CPAP-based treatment and invasive surgery is needed to place the 
implanted neurostimulator. Thus, patient eligibility is an important task to select patients who 
will really benefit from this therapy in the context of electrical nerve stimulation. In this regard, 
the invention by Q. Ni [119] describes a methodology for patient screening. Firstly, the method 
builds an obstruction feature vector composed of the location, pattern, and degree of the 
obstruction based on the analysis of upper airway images, as well as pressure and airflow 
recordings during respiration. Then, the system derives a patient candidate profile by applying 
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a patient candidate filter to the patient health history, composed of the CPAP compliance 
history, co-morbidities, BMI, and the AHI. Finally, a patient evaluation module uses the patient 
candidate information and the obstruction vector to automatically determine patient eligibility 
for electrical nerve stimulation therapy. Regarding stimulation lead characteristics, the patent 
by Johnson et al. describes an electrode cuff for easy placement as well as secure and suitable 
electrical stimulation [120]. The invention illustrates the different modules composing the 
electrode cuff, their lengths and widths, and the number, disposition, and separation of the 
electrodes along the stimulation lead in different embodiments. In addition, a method of 
implanting the detailed electrode cuff is described. 
The Nyxoah’s neuromodulator (Nyxoah, Mont-Saint-Guibert, Belgium) is an ultra-small 
system for electrical stimulation of the nerves of the tongue to prevent upper airway collapse. 
Unlike similar solutions, the implant module is extremely small because it has no internal 
battery: the energy is supplied by means of an external disposable battery patch. In addition, 
there are no wires contacting the nerves because stimulation is performed through an electric 
field, which simplifies the surgery procedure. The Nyxoah’s technology is protected by a group 
of granted patents. Patent documents by Mashiach and Mueller [125] and Mashiach [126] 
describe a methodology to detect tongue movements based on the degree of coupling 
(capacitive coupling, radiofrequency coupling, or inductive coupling) between a primary 
antenna associated with an external processor and a secondary antenna integrated in an 
implanted unit in contact with the patient’s tongue muscle. The external processor determine if 
a movement is indicative of a precursor to sleep disordered breathing and sends a control signal 
to the implant in order to cause the contraction of the muscle. The characteristics of the 
modulation control signal (voltage amplitude, current amplitude, pulse frequency, or pulse 
duration) are related to the severity of the sleep disordered breathing. One of the main 
advantages of the Nyxoah’s technology is that the implanted unit does not require contact with 
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the nerve to achieve effective neurostimulation. Patents by Mashiach [127-129] describe this 
novelty. The noncontacting stimulation is based on the so called nerve modulation, which uses 
field-generating electrodes to regulate nerve activity through delivery of energy. The internal 
unit includes modulation electrodes located in the vicinity of the target nerve (the nerve to be 
modulated, e.g. next to the subject’s tongue in the vicinity of the hypoglossal nerve). These 
electrodes generate an electric filed in response of a control signal so that a portion of the field 
lines extend along the length of the nerve. Efficacy of modulation increases when parallel 
electric field lines run partially or substantially parallel to the nerve fibers to be modulated. The 
electric field provides energy to the nerve and creates an adequate voltage change to activate 
the nerve and propagate an electrical signal. Regarding the power source of the battery-less 
internal unit, the energy is transferred to the implant from the external unit by means of 
electromagnetic signals, e.g. microwave, infrared, or radio-frequency. A control signal is 
applied to the primary (external) antenna in order to supply power to the implant. Then, a new 
signal is induced on the secondary (internal) antenna. This induced signal is transformed using 
active and/or passive circuit components and supplied to the electrodes for generating the 
electromagnetic field. Patent documents [129-131] describe the characteristics of the signals 
used both to activate the implant and to cause muscular contraction. 
Recent studies assessed long-term effects of commercial hypoglossal neurostimulator devices 
[60, 61]. In the study by Mwenge et al. [60], the AURA6000™ (ImThera, San Diego, CA, 
USA) was implanted on a population of 13 severe OSAHS patients. After a 12-month-long 
study, 10 patients showed a significant decrease in AHI, microarousal index and ODI. Fatigue 
due to continuous stimulation was not reported [60]. By contrast, surgery related complications 
(transient ipsilateral hemitongue paresis) and/or adverse events due to technical malfunction 
(transient therapy interruption, inappropriate stimulation or even component replacement) were 
reported [60]. In the study by Strollo et al. [61], clinical safety and effectiveness of the Inspire 
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UAS system (Inspire Medical Systems Inc., Maple Grove, MN, USA) was assessed in a 
population composed of 126 participants with moderate-to-severe OSAHS. Both AHI and 
ODI4 significantly decreased at the 12-month follow up compared with baseline scores. On the 
other hand, some adverse events were also reported, which included device repositioning due 
to serious discomfort (1.6% patients), temporary tongue weakness (18% patients), discomfort 
due to inappropriate stimulation (40%), tongue soreness and/or abrasion (21%). Regarding 
residual effects of hypoglossal neurostimulation therapy after treatment withdrawal, Rodenstein 
et al. showed a significant clinical residual effect at least during one night, i.e. OSAHS 
symptoms did not reappear when the treatment stopped [132]. Conversely, CPAP is 
characterized by limited intranight and night-to-night effect. On the other hand, Woodson et al. 
reported that apnea events and associated daytime symptoms reappeared after 1-week treatment 
withdrawal [133]. Similarly, Eastwood et al. [62] recently carried out a multicenter study 
involving 21 moderate-to-severe OSAHS patients to test the efficiency of the HGNS® 
neurostimulator system (Roseville, MN, USA). After 3 month-long therapy, the Authors 
reported a decrease in mean AHI by 56% (from 43 to 19), with decreases in total and 
respiratory-related arousals (47% and 66%, respectively). Sleepiness, sleep quality and quality 
of life questionnaire scores also improved [62]. However, 71% of patients reported at least one 
adverse event including tongue abrasion. Furthermore, the results suggested that a BMI greater 
than or equal to 35 kg/m2 would be an indicator of poor performance. 
Appropriate identification of those patients more likely to benefit from electrical nerve 
stimulation is an important task to optimize therapy success. In this regard, two relevant studies 
have been carried out in the context of safety and efficacy assessment of the Inspire II UAS 
system (Inspire Medical Systems Inc., Maple Grove, MN, USA) [134, 135]. In the study by 
Van de Heyning et al., the device was implanted in a population of moderate to severe OSAHS 
patients who failed o were intolerant to CPAP. The goal was to derive therapy success 
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predictors [134]. Responders met the following criteria: BMI  32 kg/m2, 20 e/h < AHI  50 
e/h, and did not show complete concentric collapse (CCC) at the level of soft palate, as 
determined by drug-induced sleep endoscopy (DISE). The assessment of these predictors as 
patient selection criteria reported significant reduction (p-value < 0.01) of AHI from baseline, 
as well as significant improvement in the Epworth Sleepiness Scale (p-value < 0.01) and 
Functional Outcomes of Sleep Questionnaire (p-value = 0.02) at 6-month postimplant follow-
up. Similarly, in the study by Vanderveken et al., the DISE procedure was assessed as a single 
tool to predict therapy success before the UAS system implantation [135]. A population 
composed of 21 patients with moderate to severe OSAHS (AHI  15 e/h) and BMI < 35 kg/m2 
were involved in the study. Treatment success was defined as AHI < 20 e/h after treatment and 
AHI reduction >50% from baseline. The results showed 81% (13/16) therapy success in the 
subset of patients without CCC at the level of the palate, whereas no treatment success was 
reported (0/5) in patients with CCC. Significant reduction of AHI (p-value < 0.001) from 
baseline and significant improvement of EES (p-value = 0.02) were reported. 
 
 
5. Conclusion 
OSAHS is a highly prevalent disease that has become a major health problem. Despite its severe 
consequences to patient’s health and quality of life, it is considered underdiagnosed and 
untreated. CPAP treatment is currently the standard of care for OSAHS. It is considered the 
most effective method for avoiding obstruction of the upper airway during sleep. However, 
several long-term trials have evidenced that patient’s adherence to therapy is not high enough. 
In this regard, unnecessary high pressure while the patient is awake, insufficient pressure level 
during obstructive events and leakage due to poor fitness to patient’s physiognomy limit 
patient’s comfort and treatment compliance. In order to overcome these limitations, several 
patents have been granted in the past few years. Inventions are mainly aimed at automatically 
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detecting airflow limitation and computing the optimal pressure for the patient, according to 
respiratory phases and changing needs during the night (normal vs. disturbance breathing and 
sleep vs. awake). Nevertheless, while non-fix pressure devices incorporating these advances are 
at present commonly prescribed, several studies have shown no clear evidences whether APAP 
and BPAP yield to improved compliance, comfort, and nocturnal or daytime symptoms. 
Therefore, based on current and extensive clinical experience, we can conclude that constant 
CPAP may be as effective and preferred by patients as proposed PAP-based alternatives. On 
the other hand, an important effort has been also carried out during the last decade to optimize 
patient’s masks in order to minimize breathing gas leakage, which has led to an actual 
improvement in patient’s comfort. Alternative therapies to CPAP include behavioral, 
pharmacological, and surgical approaches, as well as custom-made oral appliances. While 
changes in life style and pharmacologic agents are usually adjunctive therapies aimed at 
improving AHI, surgery and oral appliances are actual primary or secondary treatment options 
for OSAHS. Nevertheless, less invasive and non-permanent alternatives are needed. In this 
regard, stimulation of the hypoglossal nerve by means of implanted electrodes focuses the 
interest of physicians and researchers. In this context, different patents have been granted, 
mainly aimed at optimal selective stimulation of nerve and muscles responsible for airway 
patency and automated triggering of the electrical stimulus. However, surgery related 
complications and adverse events due to technical malfunction of the implanted neurostimulator 
are important limitations. The large number of patent applications linked with OSAHS 
treatment available in recent years points out the still increasing demand for reliable and 
effective therapies for this disease. 
 
6. Expert opinion 
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CPAP is considered the most effective treatment for OSAHS and it is currently the standard of 
care. Despite being reliable and efficient, user’s discomfort limits patient’s adherence to the 
treatment. CPAP devices have significantly evolved since this therapy was firstly described as 
a non-invasive alternative to tracheotomy. Nevertheless, there is still room for improvement as 
evidenced by the large number of patents granted in the last few years. The reviewed CPAP-
related inventions can be grouped on (i) techniques for computing the minimal pressure that fits 
the patient’s needs and (ii) apparatus for minimizing breathing gas leakage. The former mainly 
depend on signal processing techniques for the segmentation of respiratory phases (inspiration 
and expiration) and the detection of obstructive events, in order to gradually increase or 
decrease the delivered pressure. However, few details are provided concerning the performance 
of these techniques. The latter group of patents mainly depends on manufacturability and 
reproducibility of the proposed devices. Some of the major companies operating in the sleep 
apnea therapy market (ResMed Inc., Philips Respironics, Fisher & Paykel or Air Liquide) are 
assignees of some of these patents. However, extensive research to obtain solid evidences on 
the usefulness, benefits and differences with similar alternatives is needed for actual successful 
commercialization. On the other hand, electrical stimulation of the hypoglossal nerve currently 
focuses the attention of the researcher and medical community. In this regard, several patents 
have been granted during the last years describing surgical implantation procedures, as well as 
electrode and electrical stimulation characteristics. Furthermore, the FDA recently approved 
the commercialization of the Inspire II, an implantable device based on electrical stimulation 
of the hypoglossal nerve for the treatment of moderate to severe OSAHS patients who cannot 
tolerate conventional CPAP therapy. Safety and effectiveness of this commercial device have 
been assessed by means of significant clinical trials, which have led to several granted patents, 
research papers, and finally the FDA approval. In addition, it is important to highlight the 
novelty of the Nyxoah’s technology. Although the goal is essentially the same, i.e. electrical 
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stimulation of nerves, the implant is significantly smaller than its competitors, electrodes do not 
require contact with the nerve to deliver electrical stimulation, and the power source is an 
external disposable battery patch, which simplifies surgery and maximizes the time until 
replacement. Nevertheless, extensive assessment by means of large clinical tests is still needed 
to confirm the safety and effectiveness of the device prior to commercialization. Despite the 
role of the upper airway dilator muscles in maintaining the patency of the airway is well known, 
some important issues remained regarding electrical neurostimulation for effective and 
continued treatment of OSAHS. Accurate stimulation of suitable nerves and muscles and 
fatigue prevention focused recent research. The reviewed patents linked with electrical 
stimulation can be divided into (i) continuous stimulation vs. event triggered and (ii) coarse vs. 
selective stimulation. In the first group, detection of obstructive events from respiratory-derived 
signals is essential for triggering electrical stimulation just when needed in order to manage 
fatigue. In the second group, feasible and reliable surgical techniques for the accurate 
attachment of the implantable electrode to the nerve are essential. Despite its potential benefits 
for some OSAHS patients who refuse CPAP, further research is still needed to make 
hypoglossal nerve stimulation a feasible alternative therapy to oral appliances and upper airway 
surgical procedures. Optimization of both the implantable device and the stimulation 
parameters will focus future inventions in order to overcome technical malfunction of the 
implanted neurostimulator reported in recent long-term studies. Overall, regarding both CPAP 
and electrical stimulation approaches, advanced signal processing techniques could 
significantly improve the effectiveness of these therapies. Biomedical signal processing 
provides accurate tools for the detection of respiratory events, such as nonlinear forecasting, 
statistical classifiers, neural networks, support vector machines, or ensemble learning, among 
others. This would allow for optimal delivery of positive pressure and electrical stimulus, 
improving patient’s comfort and adherence to treatment. 
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Tables 
Therapy approach Modalities Advantages Disadvantages 
Positive airway 
pressure devices 
- Continuous (CPAP) 
- Bi-level (BPAP) 
- Self-adjusting (Auto-PAP) 
- Non-invasive 
- Reversible 
- Highly effective 
- Leakage 
- Patient’s discomfort 
(dryness, irritation) 
- Low compliance 
Oral appliances - Tongue retaining 
- Mandibular repositioning 
- Removable 
- Custom-made 
- Pain 
- Irritation 
- Excessive salivation 
Surgical - Hyoid suspension 
- Uvulopalatopharyngoplasty 
- Maxillomandibular advancement 
- Effective in 
selected patients 
- Non-reversible 
- Highly invasive 
Behavioral and 
pharmacological 
- Life style changes (weight loss, 
sleep position change) 
- Supplemental oxygen, modafinil 
- Non-invasive 
- Reversible 
- Adjunctive therapies to 
additional primary 
treatment 
Electrical nerve 
stimulation 
- Event triggered 
- Continuous stimulation 
- Removable 
implanted device 
- No compliance 
issues linked with 
uncomfortable 
appliances 
- Needs surgery 
- Muscle and nerve 
fatigue 
- Induced arousals 
Table 1. Overview of the main therapies currently available for OSAHS treatment, advantages 
and limitations. 
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Therapy 
approach 
Title (number) Main features of patented invention Ref. 
Positive airway 
pressure 
delivery (auto-
adjusting) 
System for optimizing 
continuous positive airway 
pressure for treatment of 
obstructive sleep apnea 
(AU705270) (CA2190488) 
(EP0759791) (EP1172123) 
Method and apparatus for 
optimizing the continuous 
positive airway pressure for 
treating obstructive sleep apnea 
(US6299581) (US6488634) 
(US6793629) 
(US7901361) 
System and method for 
classifying patient’s breathing 
using artificial neural network 
(US7276031) 
Automated detection of airflow limitation 
based on shaped-based parameters derived 
from airflow monitoring using signal 
processing methods (logistic regression 
and decision tree). The invention can be 
used either for treatment or for diagnostic 
purposes. 
 
 
 
 
 
Automated classification of airflow 
limitation using a pre-trained artificial 
neural network. 
[64-67] 
 
 
 
 
[68-70,72] 
 
 
 
 
 
 
 [71] 
Positive airway 
pressure 
delivery (auto-
adjusting) 
Auto CPAP (US6889691) The system detects patterns characteristic 
of sleep disordered breathing to control the 
pressure of gas delivered to a patient. 
Airflow is parameterized by the cesptrum 
coefficients and the energy content, which 
are fed to an artificial neural network to 
detect airflow limitation. 
[73] 
Positive airway 
pressure 
delivery (auto-
adjusting) 
Detection and prediction of 
physiological events in people 
with sleep disordered breathing 
The invention applies advanced signal 
processing techniques (Wavelet transform 
and LAMSTAR neural networks) to detect 
and predict respiratory events from 
[74] 
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using a LAMSTAR neural 
network (US8775340) 
physiological recordings, in order to 
modulate the pressure level according to 
the patient’s needs.  
Positive airway 
pressure 
delivery (auto-
adjusting) 
Multilevel ventilator 
(EP1750581) 
The proposed system performs pattern 
recognition by means of a plurality of 
artificial neural networks to control the 
breathing support. 
[75] 
Positive airway 
pressure 
delivery (auto-
adjusting) 
Positive airway pressure system 
and method for treatment of 
sleeping disorder in patient 
(US6988994) 
Signal processing techniques are applied 
to analyze breathing patterns in order to 
detect wakefulness, sleep, normal 
breathing and disturbance breathing. As a 
result, the airflow pressure delivered to the 
patient is varied. 
[78] 
Positive airway 
pressure 
delivery (auto-
adjusting) 
System, apparatus and method 
for supplying gases 
(US2014/0000610A1) 
The system delivers a therapeutic pressure 
level when the patient is asleep and a lower 
pressure when the user is awake. 
[79] 
Positive airway 
pressure 
delivery (auto-
adjusting) 
Apparatus and method for 
providing gases to a user 
(US2013/0133656A1) 
The system analyzes breathing patterns 
and user interactions with the PAP device 
to detect sleep onset and wakefulness.  
[80] 
Positive airway 
pressure 
delivery (auto-
adjusting) 
Apparatus for providing positive 
airway pressure to a patient 
(AU2003295925) (CA2507254) 
(EP1565224) 
Method and apparatus for 
providing positive airway 
pressure to a patient 
(US6932084) (US7296573) 
(US7810496) (EP1061981) 
The system computes the optimal 
minimum pressure during inspiration and 
expiration depending on the estimated 
patient’s flow rate. The invention is able to 
detect obstructive apneas, hypopneas and 
central apneas. 
[81,82,84] 
 
 
 
[83,85-
87] 
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Positive airway 
pressure 
delivery (auto-
adjusting) 
Parameter optimization in sleep 
apnea treatment apparatus 
(US7469698) (US7926486) 
The invention describes a methodology 
and a system for managing therapy at 
home. Prescribed or auto-adjusting custom 
pressure parameters can be set in the 
system to optimize the delivered pressure. 
[88,89] 
Positive airway 
pressure 
delivery (bi-
level) 
Method and apparatus for 
providing positive airway 
pressure to a patient 
(US8256417) 
Apparatus for providing positive 
airway pressure to a patient 
(US8684001) 
Improvement of synchrony between 
patient’s inspiration and expiration stages 
and bi-level delivered pressure. 
Correlation between monitored patient’s 
airflow signal and delivered pressure 
signal is used. 
[90] 
 
 
[91] 
Positive airway 
pressure 
delivery (bi-
level) 
Automatic positive airway 
pressure therapy through the nose 
or mouth for treatment of sleep 
apnea and other respiratory 
disorders (US8316847) 
Automated optimization of IPAP and 
EPAP delivered pressures based on 
respiratory-related parameters. 
[92] 
Positive airway 
pressure 
delivery 
(complete 
enclosure) 
CPAP enclosure for the treatment 
of sleep apnea (US7520277) 
A complete enclosure is described to 
provide PAP therapy without the need for 
a fitted mask. 
[94] 
Positive airway 
pressure 
delivery (flow 
diverter) 
Flow diverter for controlling the 
pressure and flow rate in a CPAP 
device (US6745770) 
(US6895964) (AU2002324018) 
(US7036506) (US7527055) 
(US7694679) 
Delivered breathing gas pressure is 
controlled by means of a flow diverter 
rotatable vane inserted between the patient 
mask and the flow generator. 
[95-100] 
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Positive airway 
pressure 
delivery (facial 
mask) 
Improved membrane cushion for 
facial mask for treating sleep 
disorders (EP2478925) 
The invention describes a cushion for a 
respiratory mask able to deliver efficient 
gas tightness whatever the patient’s 
physiognomy. 
[101] 
Positive airway 
pressure 
delivery (facial 
mask) 
Cushion for a respiratory mask 
assembly (US7523754) 
The invention describes a cushion for 
controlling the distribution of contact 
force of a respiratory mask around the 
patient’s face. 
[102] 
Positive airway 
pressure 
delivery (facial 
mask) 
Nasal mask and system using 
same (US6959710) 
The invention describes different 
structures and areas of a cushion designed 
to control the contact area of the mask-
patient interface. 
[103] 
Electrical nerve 
stimulation 
(continuous) 
RFID-based apparatus, system, 
and method for therapeutic 
treatment of obstructive sleep 
apnea (US7725195) 
Apparatus, system, and method 
for therapeutic treatment of 
obstructive sleep apnea 
(US7937159) 
RFID-enabled microelectronic 
neurostimulator system. The system 
performs selective stimulation of 
hypoglossus and styloglosus by means of 
multiple nerve stimulating points. 
[105] 
 
 
 
[106] 
Electrical nerve 
stimulation 
(continuous) 
Method of stimulating a 
hypoglossal nerve for controlling 
the position of a patient’s tongue 
(AU2009302591) (US8428725) 
(US8751005) 
The invention describes a method for 
selective electrical stimulation of the 
motor efferents of the hypoglossal nerve. 
Continuous but controlled stimuli are 
delivered to minimize fatigue 
[63,107, 
108] 
Electrical nerve 
stimulation 
(event 
triggered) 
Apparatus and method for 
treating obstructive sleep apnea 
(US8249723) (US8359108) 
(US8774943) 
The invention monitors the position of the 
tongue to detect obstructive events (the 
tongue moves onto the airway causing the 
apnea). Then, electrical stimuli are 
delivered to the branches of the motor 
[109-111] 
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nerves of the tongue to recover airway 
patency. 
Electrical nerve 
stimulation 
(event 
triggered) 
Obstructive sleep apnea 
treatment devices, systems and 
methods (US7809442) 
(US8311645) (US8428727) 
(US8639354) (US8718783) 
The proposed system detects respiratory 
events by means of external and/or 
implanted sensors to trigger electrical 
stimuli. Different signal processing stages 
are applied to compute respiratory-derived 
control parameters. 
[112-116] 
Electrical nerve 
stimulation 
(pre-surgery 
test) 
Screening devices and methods 
for obstructive sleep apnea 
therapy (US8386046) 
The inventors describe a methodology for 
assessing the likelihood of therapeutic 
success of electrical stimulation before the 
surgery. 
[117] 
Electrical nerve 
stimulation 
(event 
triggered) 
System for treating sleep 
disordered breathing 
(US8938299) 
System and method for patient 
selection in treating sleep 
disordered breathing 
(US8983572) 
Nerve cuff (US8934992) 
Recent granted patents by Inspire Medical 
Systems Inc.: 
(i) Automatic therapy manager based on 
respiration and body position (activity and 
posture) monitoring. 
(ii) Methodology for patient screening 
based on medical images and biosignals 
and the patient’s health history. 
(iii) Stimulating electrode characteristics. 
 
 
[118] 
 
 
[119] 
 
 
[120] 
Electrical nerve 
stimulation 
(event 
triggered) 
Transvenous method of treating 
sleep apnea 
(US2011/0202119A1) 
Percutaneous access for systems 
and methods of treating sleep 
apnea (US2012/0089153A1) 
Method and system for 
identifying a location for nerve 
Recent patent applications by Inspire 
Medical Systems Inc.: 
(i) Minimally invasive techniques for 
insertion of sensing and stimulation leads. 
(ii) Technique for suitable electrode 
positioning. 
(iii) Methodology for respiratory effort 
monitoring to control the therapy level. 
 
 
[121, 122] 
 
[123] 
 
[124] 
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stimulation 
(US2013/0204097A1) 
Method and apparatus for sensing 
respiratory pressure in an 
implantable stimulation system 
(US2011/0152706A1) 
Electrical nerve 
stimulation 
(event 
triggered) 
Systems and methods for 
determining sleep disorder based 
on positioning of the tongue 
(US8577472) 
Apparatus and method for 
detecting a sleep disordered 
breathing precursor (US8574164) 
System and method for nerve 
modulation using noncontacting 
electrodes (US8577466) 
Device and method for 
modulating nerves using parallel 
electric fields (US8588941) 
Devices and methods for low 
current neural modulation 
(US8700183) 
Apparatus and method to control 
an implant (US8718776) 
Apparatus and method for 
extending implant life using a 
dual power scheme (US8577468) 
Nyxoah’s neuromodulator technology: 
(i) Methodology to detect tongue 
movements based on the degree of 
coupling between adjacent antennas. 
(ii) Description of the nerve modulation 
technique based on non-contacting field-
generating electrodes. 
(iii) Methodology for power supplying to 
an implant from the external unit by means 
of electromagnetic fields. 
 
[125, 126] 
 
 
[127-129] 
 
 
[130, 131] 
Table 2. Reviewed granted patents (2005 – 2014) related to PAP and electrical nerve 
stimulation therapies for OSAHS treatment. 
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List of abbreviations 
AASM: American Academy of Sleep Medicine 
AF: airflow 
AHI: apnea-hypopnea index 
Auto-PAP: auto-adjusting continuous positive airway pressure 
BPAP: bi-level positive airway pressure 
CCC: complete concentric collapse 
CPAP: continuous positive airway pressure 
CV: coefficient of variation 
DISE: drug-induced sleep endoscopy 
ECG: electrocardiogram 
EEG: electroencephalogram 
EMG: electromyogram 
EOG: electrooculogram 
EPAP: expiratory positive airway pressure 
FDA: U.S. Food and Drug Administration 
IPAP: inspiratory positive airway pressure 
OSAHS: obstructive sleep apnea-hypopnea syndrome 
PAP: positive airway pressure 
PP: peak-to-peak 
PPAP: proportional positive airway pressure 
PPmax: maximum PP amplitude 
PPmin: minimum PP amplitude 
PSG: polysomnography 
RFID: radio frequency identification 
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SpO2: blood oxygen saturation 
UAS: upper airway stimulation 
